PTC Inc. (PTC)
PTC, Microsoft & Volkswagen Collaborate on Codebeamer AI Copilot
PTC partners with MSFT and Volkswagen for a Codebeamer AI Copilot designed to simplify product development.
PTC Therapeutics Stock Soars on Novartis Licensing Agreement
Shares of PTC Therapeutics (PTCT) soared 16% Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and collaboration deal with Novartis (NVS).
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
On Monday, PTC Therapeutics, Inc. PTCT signed an exclusive global license and collaboration agreement with Novartis AG NVS for its PTC518 Huntington's disease program, which includes related molecules.
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone
Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.
PTC Therapeutics signs up to $1.9 billion licensing deal with Novartis
PTC Therapeutics has entered into a licensing deal with a unit of Novartis AG for up to $1.9 billion, the company said on Monday, for its experimental drug being developed for a rare neurological disorder.
PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs
On Tuesday, PTC Therapeutics Inc PTCT revealed data from the global Phase 2 placebo-controlled CardinALS study of Utreloxastat in amyotrophic lateral sclerosis patients.
PTC Therapeutics discontinues development of ALS drug after trial failure
PTC Therapeutics said on Tuesday it is discontinuing the development of its drug for a type of fatal neurodegenerative disease, as it did not meet the main goal in a mid-stage trial.
A Few Years From Now, You'll Wish You'd Bought This Undervalued Stock
A Few Years From Now, You'll Wish You'd Bought This Undervalued Stock
US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder
The U.S. Food and Drug Administration approved PTC Therapeutics' gene therapy that is administered directly in the brain to treat a potential fatal enzyme deficiency disorder, the company said on Wednesday.
PTC's Q4 Earnings Surpass Estimates, Revenues Rise Y/Y, Shares Jump
PTC's Q4 performance is driven by steady growth in recurring revenues amid a tough sales backdrop.
PTC Inc. (PTC) Q4 2024 Earnings Call Transcript
PTC Inc. (PTC) Q4 2024 Earnings Call Transcript
Compared to Estimates, PTC Inc. (PTC) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for PTC Inc. (PTC) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
